TIGIT and glioma: Anti-PD-1 therapy was also efficient in prolonging the survival of GL261 glioma-bearing mice, particularly when combined with anti-T cell immunoglobulin and ITIM domain (TIGIT) therapy [47], where TIGIT is an immune checkpoint receptor that plays a critical role in cancer immunity [48].